Get the Stockscreener App
0.807
0.38%
-0.0031
After Hours:
.805
-0.002
-0.25%
Viracta Therapeutics Inc stock is currently priced at $0.807, with a 24-hour trading volume of 70,761.
It has seen a -0.38% decreased in the last 24 hours and a -13.81% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.8346 pivot point. If it approaches the $0.7755 support level, significant changes may occur.
Previous Close:
$0.8101
Open:
$0.805
24h Volume:
70,761
Market Cap:
$31.69M
Revenue:
-
Net Income/Loss:
$-51.06M
P/E Ratio:
-0.5848
EPS:
-1.38
Net Cash Flow:
$-40.03M
1W Performance:
+6.18%
1M Performance:
-13.81%
6M Performance:
+39.31%
1Y Performance:
-52.81%
1D Range:
$0.805
$0.87
52W Range:
$0.43
$2.38
Viracta Therapeutics Inc Stock (VIRX) Company Profile
Name
Viracta Therapeutics Inc
Sector
Industry
Phone
858 400 8470
Address
2533 South Coast Highway 101, Suite 210, Cardiff-by-the-Sea
Viracta Therapeutics Inc Stock (VIRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-01-22 | Initiated | RBC Capital Mkts | Outperform |
| May-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Initiated | SVB Leerink | Outperform |
| Mar-25-21 | Initiated | Evercore ISI | Outperform |
Viracta Therapeutics Inc Stock (VIRX) Latest News
Viracta Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
GlobeNewswire
Viracta Therapeutics Announces New Employment Inducement Grants
GlobeNewswire Inc.
Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday? - MSN
MSN
Viracta Therapeutics appoints Michael Faerm as CFO By Investing.com - Investing.com
Investing.com
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer - GlobeNewswire
GlobeNewswire
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer - Yahoo Finance UK
Yahoo Finance UK
Viracta Therapeutics Inc Stock (VIRX) Financials Data
Viracta Therapeutics Inc (VIRX) Net Income 2024
VIRX net income (TTM) was -$51.06 million for the quarter ending December 31, 2023, a -3.78% decrease year-over-year.
Viracta Therapeutics Inc (VIRX) Cash Flow 2024
VIRX recorded a free cash flow (TTM) of -$40.03 million for the quarter ending December 31, 2023, a -12.75% decrease year-over-year.
Viracta Therapeutics Inc (VIRX) Earnings per Share 2024
VIRX earnings per share (TTM) was -$1.32 for the quarter ending December 31, 2023, a -1.54% decline year-over-year.
Viracta Therapeutics Inc Stock (VIRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chevallard Daniel R. | CFO and COO |
Feb 25 '24 |
Option Exercise |
0.00 |
6,889 |
0 |
105,711 |
| ROYSTON IVOR | Director |
Feb 25 '24 |
Option Exercise |
0.00 |
25,219 |
0 |
764,084 |
| Pomerantz Roger | Director |
Feb 25 '24 |
Option Exercise |
0.00 |
9,034 |
0 |
99,375 |
| Rothera Mark | President and CEO |
Dec 01 '23 |
Buy |
0.49 |
47,906 |
23,627 |
100,000 |
| Rothera Mark | President and CEO |
Nov 30 '23 |
Buy |
0.49 |
52,094 |
25,734 |
52,094 |
| Chevallard Daniel R. | CFO and COO |
Nov 28 '23 |
Sale |
0.50 |
3,720 |
1,860 |
98,822 |
| Chevallard Daniel R. | CFO and COO |
Nov 25 '23 |
Option Exercise |
0.00 |
6,889 |
0 |
102,542 |
| ROYSTON IVOR | Director |
Nov 25 '23 |
Option Exercise |
0.00 |
25,219 |
0 |
738,865 |
| Pomerantz Roger | Director |
Nov 25 '23 |
Option Exercise |
0.00 |
9,034 |
0 |
90,341 |
| Chevallard Daniel R. | CFO and COO |
Aug 28 '23 |
Sale |
1.45 |
3,512 |
5,092 |
95,653 |
About Viracta Therapeutics Inc
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
0.77%
1.20%
Cap:
|
Volume (24h):